Nazartinib
- Generic Name
- Nazartinib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C26H31ClN6O2
- CAS Number
- 1508250-71-2
- Unique Ingredient Identifier
- KE7K32EME8
- Background
Nazartinib is under investigation in clinical trial NCT03529084 (Phase III Study of Nazartinib (EGF816) Versus Erlotinib/gefitinib in First-line Locally Advanced / Metastatic NSCLC With EGFR Activating Mutations).
- Associated Conditions
- -
- Associated Therapies
- -
Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2017-02-02
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 40
- Registration Number
- NCT03040973
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇪🇸Novartis Investigative Site, Madrid, Spain
Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Adult Patients With EGFR Mutated Non Small Cell Lung Cancer.
- First Posted Date
- 2015-01-12
- Last Posted Date
- 2023-06-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 177
- Registration Number
- NCT02335944
- Locations
- 🇨🇳
Novartis Investigative Site, Taipei, Taiwan ROC, Taiwan
🇺🇸Massachusetts General Hospital Mass General, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath